As of December 31, 2022, cash and cash equivalents were $155.4 million. An additional $100 million is available under Phathom’s term loan with Hercules Capital. Based on its current operating plan, including the funds currently available under its existing term loan and following approval of vonoprazan for erosive GERD, available under its royalty interest financing agreement, Phathom believes it will have sufficient capital to fund operations through 2024.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PHAT:
- Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- PHAT Nosedives on Vonoprazan Uncertainties
- Phathom Pharmaceuticals discloses FDA CRL on certain products
- Phathom Pharmaceuticals Provides Regulatory Updates
- Phathom Pharmaceuticals price target lowered to $22 from $30 at Guggenheim
